On the other hand, there is mounting evidence of AURKA (Aurora Kinase A) and EZH2 proteins as possible targets for cancer therapy in a variety of cancers [75,76,77,78,79,80,81,82] and specific inhibitors, such as alisertib (targeting AURKA) and tazemetostat (targeting EZH2) that are commercially available, which make them ideal compounds for the next steps of drug testing in our system. The gene discussed is AURKA; the disease is cancer.